Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare, serious post–COVID-19 hyperinflammatory condition affecting children and adolescents. It appears weeks after SARS‑CoV‑2 exposure with persistent fever, abdominal pain, vomiting, rash, conjunctivitis, mucous membrane changes, low blood pressure, and cardiac dysfunction. Lab tests show elevated inflammatory markers. MIS‑C can progress to shock and requires prompt hospitalization, immunomodulatory therapy (IVIG, steroids) and supportive care.

Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but serious post‑infectious inflammatory condition occurring weeks after COVID‑19. It features persistent fever, elevated inflammatory markers, and multisystem organ involvement—commonly heart, blood vessels, lungs, kidneys, gastrointestinal tract, skin, eyes, or nervous system. MIS-C can cause shock and cardiac dysfunction and requires urgent medical evaluation and treatment, often including anti-inflammatory and supportive therapies.

Multisystem inflammatory syndrome in children (MIS-C) typically presents several weeks after COVID-19 and often includes persistent high fever, severe abdominal pain, vomiting or diarrhea, rash, red eyes (conjunctivitis), swollen hands or feet, red cracked lips or tongue, swollen lymph nodes, extreme fatigue, headache, and difficulty breathing. It can cause rapid heartbeat, low blood pressure or shock—any child with these signs needs urgent medical evaluation.

MIS‑C’s acute inflammatory phase usually lasts days to a few weeks, with many children improving within 1–2 weeks after prompt treatment (IVIG, steroids); hospital stays often span several days to a couple of weeks. Full recovery, especially cardiac monitoring and resolution of inflammation, can take weeks to months. Long-term follow-up is recommended to check and manage any lingering heart or inflammatory issues.

MIS-C stands for Multisystem Inflammatory Syndrome in Children. It’s a rare but serious post‑COVID condition where widespread inflammation affects two or more organ systems (heart, lungs, kidneys, brain, skin, GI). Typical signs include persistent fever, abdominal pain, vomiting, diarrhea, rash, conjunctivitis, low blood pressure and shock. It requires urgent medical evaluation; treatment often needs hospital care with immune‑modulating therapy and supportive measures.

MIS-C is treated in hospital with supportive care and close monitoring, often including IV immunoglobulin (IVIG) and corticosteroids to reduce inflammation. Aspirin or anticoagulation may be used to prevent clots, and additional immune therapies (e.g., biologics) are considered if needed. Cardiac monitoring, fluid and blood pressure support, and antibiotics until infection is excluded are commonly provided.